Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin (TOP)

This study has been terminated.
(Low accrual rate)
Sponsor:
Collaborators:
Gustave Roussy, Cancer Campus, Grand Paris
Centre Paul Strauss
Centre Hospitalier du Luxembourg
Clinique Louis Cathy - Baudour - Belgium
HIS - Site Etterbeek - Ixelles - Belgium
Clinique Saint Pierre - Ottignies -Belgium
Clinique Ste Elisabeth - Namur - Belgium
University Hospital of Crete
Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Information provided by:
Jules Bordet Institute
ClinicalTrials.gov Identifier:
NCT00162812
First received: September 9, 2005
Last updated: July 16, 2008
Last verified: July 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2009
  Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)